A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Description

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

Conditions

Advanced Breast Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Condition
Advanced Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Springdale

Highlands Oncology Group, Springdale, Arkansas, United States, 72762

Los Angeles

UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States, 90064-2320

New Haven

Yale Comprehensive Cancer Center, New Haven, Connecticut, United States, 06510

Altamonte Springs

Advent Health (Florida Hospital), Altamonte Springs, Florida, United States, 32701

Lady Lake

Florida Cancer Specialists & Research Institute (FCS) - Villages East, Lady Lake, Florida, United States, 32159

Sarasota

Florida Cancer Specialists & Research Institute (FCS) - Sarasota, Sarasota, Florida, United States, 34232

Baltimore

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States, 21231

Boston

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States, 02114

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Grand Rapids

START Midwest - Oncology, Grand Rapids, Michigan, United States, 49546

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants with advanced breast cancer that cannot be cured.
  • * Participant must have received at least one prior line of endocrine therapy for advanced/metastatic disease. Progression on previous cyclin-dependent kinase 4/6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required.
  • * Up to 6 prior lines of therapy are allowed. Up to 2 prior chemotherapy and/or cytotoxic antibody-drug conjugates regimens in the advanced/metastatic setting is permitted.
  • * New or active brain metastasis.
  • * Severe internal organ spread that could cause immediate life-threatening problems, including large uncontrolled fluid build-up or severe lung or liver involvement.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stemline Therapeutics, Inc.,

Study Record Dates

2026-10